You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD19 positive

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

CD19-positive Relapsed or Refractory B-cell Malignancies Trial in Hefei (UTAA09 cells for infusion, Fludarabine,

Not yet recruiting
  • CD19-positive Relapsed or Refractory B-cell Malignancies
  • UTAA09 cells for infusion
  • +2 more
  • Hefei, Anhui, China
    The First Affiliated Hospital of USTC (AnHui Provincial Hospital
Oct 13, 2023

Non-hodgkin Lymphoma, Acute Lymphoblastic Leukaemia, Chronic Lymphocytic Leukemia Trial in Tianjin (CC312)

Recruiting
  • Non-hodgkin Lymphoma
  • +2 more
  • CC312
  • Tianjin, Tianjin, China
    InstituteHBDH
Sep 12, 2023

R/R CD19-Positive B-Cell Malignancies, Indolent Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma Trial (CNTY-101, IL-2,

Recruiting
  • R/R CD19-Positive B-Cell Malignancies
  • +2 more
  • CNTY-101
  • +2 more
  • Detroit, Michigan
  • +1 more
Dec 21, 2022

Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory Trial in Columbus

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +5 more
  • CD19 specific Chimeric Antigen Receptor T Cell
  • Columbus, Ohio
    Nationwide Children's Hospital
Mar 9, 2023

Acute Lymphoblastic Leukemia in Remission Trial in Suzhou (CD19 CAR-T cells and CD19 positive feeder T cells)

Recruiting
  • Acute Lymphoblastic Leukemia in Remission
  • CD19 CAR-T cells and CD19 positive feeder T cells
  • Suzhou, Jiangsu, China
  • +2 more
May 18, 2022

Advanced Malignancies Trial in Beijing (1A46 Drug Substance)

Not yet recruiting
  • Advanced Malignancies
  • 1A46 Drug Substance
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Aug 4, 2023

Acute Lymphoblastic Leukemia Trial in Sanhe (CAR-NK-CD19 Cells)

Completed
  • Acute Lymphoblastic Leukemia
  • CAR-NK-CD19 Cells
  • Sanhe, Hebei, China
    Hebei Yanda Ludaopei Hospital
Nov 24, 2022

Relapsed or Refractory Acute Lymphoblastic Leukemia Trial in Shanghai (ssCART-19 Cells, Fludarabine, Cyclophosphamide)

Recruiting
  • Relapsed or Refractory Acute Lymphoblastic Leukemia
  • ssCART-19 Cells
  • +2 more
  • Shanghai, Shanghai, China
    Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd.
May 17, 2022

Recurrent DLBCL, Refractory Diffuse Large B-cell Lymphoma Trial in Tianjin (RC19D2 cell injection)

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-cell Lymphoma
  • RC19D2 cell injection
  • Tianjin, Tianjin, China
    Hematology Hospital of the Chinese Academy of Medical Sciences
Sep 14, 2023

Lymphomas Non-Hodgkin's B-Cell, Relapse Trial in Tianjin (CD19 CAR T cells)

Completed
  • Lymphomas Non-Hodgkin's B-Cell
  • Relapse
  • CD19 CAR T cells
  • Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Jan 24, 2022

Mixed Phenotype Acute Leukemia (MPAL), Measurable Residual Disease (MRD) Trial in Baltimore (BLINCYTO (Blinatumomab))

Recruiting
  • Mixed Phenotype Acute Leukemia (MPAL)
  • Measurable Residual Disease (MRD)
  • BLINCYTO (Blinatumomab)
  • Baltimore, Maryland
    Greenebaum Cancer Center at University of Maryland Medical Cente
Apr 18, 2022

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory, Pediatric ALL Trial in Memphis (biological,

Recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +2 more
  • CD19-CAR(Mem) T-cells
  • +5 more
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Aug 5, 2022

Non-Hodgkin's Lymphoma (Disorder), Acute Lymphoid Leukemia, Disease (Disorder) Trial in Louisville, Houston (1A46 Injection)

Recruiting
  • Non-Hodgkin's Lymphoma (Disorder)
  • Acute Lymphoid Leukemia, Disease (Disorder)
  • 1A46 Injection
  • Louisville, Kentucky
  • +1 more
Aug 1, 2022

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Refractory, B-cell Lymphoma Recurrent Trial in São Paulo

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +5 more
  • São Paulo, Brazil
    Hospital Israelita Albert Einstein
Jan 20, 2023

Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia Trial in Vancouver, Ottawa (CLIC-1901)

Recruiting
  • Acute Lymphoblastic Leukemia
  • +2 more
  • CLIC-1901
  • Vancouver, British Columbia, Canada
  • +1 more
Mar 26, 2022

Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia Trial in Wuhan (pCAR-19B cells)

Completed
  • Acute Lymphoblastic Leukemia
  • +2 more
  • pCAR-19B cells
  • Wuhan, Hubei, China
    Tongji Hospital affiliated to Tongji Medical College of Huazhong
Mar 16, 2022

Acute Lymphoblastic Leukemia, CD19 Positive, Relapse Trial in Suzhou (Humanized CD19 CAR-T cells, Humanized CD19 CAR-T cells

Recruiting
  • Acute Lymphoblastic Leukemia
  • +3 more
  • Humanized CD19 CAR-T cells
  • Humanized CD19 CAR-T cells with CRS suppression technology
  • Suzhou, Jiangsu, China
    The first affiliated hospital of soochow university
May 18, 2022

CD19-positive, Acute Lymphoblastic Leukemia Trial in Shanghai (Human CD19 targeted T Cells Injection)

Recruiting
  • CD19-positive
  • Acute Lymphoblastic Leukemia
  • Human CD19 targeted T Cells Injection
  • Shanghai, Shanghai, China
    Shanghai General Hospital
Aug 29, 2021

CD19+ Relapse/Refractory B-ALL Trial in Beijing (CAR-T-19 Cells)

Recruiting
  • CD19+ Relapse/Refractory B-ALL
  • CAR-T-19 Cells
  • Beijing, Beijing, China
    Chinese PLA General Hospital
Feb 26, 2022

CD19-positive, Diffuse Large B-cell Lymphoma, Follicular Lymphoma Trial in Nanchang, Shanghai, Wenzhou (Human CD19 targeted T

Recruiting
  • CD19-positive
  • +2 more
  • Human CD19 targeted T Cells Injection
  • Nanchang, Jiangxi, China
  • +2 more
Aug 29, 2021

Acute Lymphoblastic Leukemia Trial in Hangzhou (Blinatumomab)

Recruiting
  • Acute Lymphoblastic Leukemia
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Nov 5, 2023

B-cell Acute Lymphoblastic Leukemia Trial in Seoul (SNUH-CD19-CAR-T)

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • SNUH-CD19-CAR-T
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Feb 20, 2022

Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia Trial in China (pCAR-19B cells)

Recruiting
  • Acute Lymphoblastic Leukemia
  • +2 more
  • pCAR-19B cells
  • Beijing, Beijing, China
  • +9 more
May 19, 2022

Non-Hodgkin's Lymphoma, B-Cell ALL, B-Cell CLL Trial in Houston (CD19.CAR-CD28Z T Cells - dose escalation 2, CD19.CAR-CD28Z T

Recruiting
  • Non-Hodgkin's Lymphoma
  • +2 more
  • CD19.CAR-CD28Z T Cells - dose escalation 2
  • CD19.CAR-CD28Z T Cells - dose escalation 1
  • Houston, Texas
  • +1 more
Feb 10, 2022

Relapsed/Refractory B-Cell Malignancies Trial (CD19 Chimeric Antigen Receptor (CAR) T Cells)

Not yet recruiting
  • Relapsed/Refractory B-Cell Malignancies
  • CD19 Chimeric Antigen Receptor (CAR) T Cells
  • (no location specified)
Jun 28, 2021